



2019 Update: Barcode Readability for DSCSA 2023 Interoperability

Pharmaceutical Wholesalers Uncover Significant Progress in Barcode Assessments

In the summer 2019 and for the third consecutive year, AmerisourceBergen Corporation (AmerisourceBergen) and McKesson Pharmaceutical (McKesson) in collaboration with GS1 Healthcare US[®], assessed the barcodes of packages “lowest saleable unit” in their distribution facilities to obtain a view of industry’s progress in implementing serialization requirements of the [2013 Drug Supply Chain Security Act \(DSCSA\)](#).¹

During this same timeframe, Cardinal Health conducted its own barcode assessment of homogeneous cases from pharmaceutical manufacturers, with support from GS1 Healthcare US.

The DSCSA defines the requirements for an interoperable, electronic system to identify and trace pharmaceutical products throughout their distribution in the United States.² As part of the requirements, pharmaceutical products must be marked with a National Drug Code (NDC), serial number, lot number, and expiration date.³ (When using GS1 Standards, the NDC is represented by a GS1 Global Trade Item Number[®] or GTIN[®].)

The DSCSA also specifies that packages (known as “lowest saleable units” in industry) must be marked with a two-dimensional (2D) barcode (e.g., GS1 DataMatrix barcode), and homogeneous cases with either a 2D barcode or linear barcode (e.g., GS1-128 barcode).⁴

Assessment results offer an indicator of how many packages and cases in the market today are marked with a serialized readable barcode containing the four DSCSA-required data elements.

It is critical that barcodes are applied in a standardized way to facilitate accurate movement of product across the healthcare supply chain and to associate the physical product markings with the serialized electronic data exchange that will occur on or before November 27, 2023.

For the third consecutive year, AmerisourceBergen and McKesson conducted barcode assessments to gain an up-to-date view of industry’s progress in implementing serialization requirements of the 2013 DSCSA. Cardinal Health conducted its own barcode assessment of homogeneous cases from pharmaceutical manufacturers. All three assessments were supported by GS1 Healthcare US.

1 Drug Supply Chain Security Act, [Pub. Law No. 113-54](#), 127 Stat 599 (2013).

2 United States. Department of Health and Human Services. Food and Drug Administration (FDA) (n.d.). “Drug Supply Chain Security Act.” Accessed September 14, 2018 at: <https://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/default.htm>

3 Drug Supply Chain Security Act, [Pub. Law No. 113-54](#), § 582(b)(2)(A), 127 Stat 599, 609 (2013).

4 Drug Supply Chain Security Act, [Pub. Law No. 113-54](#), § 582(a)(9)[A], 127 Stat 599, 608 (2013).

The 2019 barcode assessments expanded the scope of analysis to include the November 27, 2023 interoperable requirements and quantify impacts of readiness in these areas. GS1 Healthcare US and the Big 3 wholesalers are participating in the U.S. Food and Drug Administration (FDA) Pilot Project Program under the Drug Supply Chain Security Act, Docket No. FDA-2016-N-0407 for the scanning, data collection, analysis, and reporting of the barcode testing pilot.

Previous barcode assessment studies were conducted by AmerisourceBergen and McKesson in 2017, and again in 2018 with the addition of Cardinal Health, each year facilitated by GS1 Healthcare US. These studies identified issues with lack of adherence to industry barcode standards and placement—problems that can result in serious consequences, such as improper identification of products, mis-shipments, reduced operational efficiency, and product availability issues.

With results from the 2019 assessments, AmerisourceBergen, Cardinal Health, and McKesson are now able to follow up and share results with their individual supplier manufacturers and repackagers so that they can continue to make any course corrections, as needed.

Scanning Methodologies

Taking a consistent, year-over-year approach, the teams from AmerisourceBergen and McKesson with collaboration from GS1 Healthcare US once again scanned 2D barcodes on product packages, capturing data to measure the percentage of readable 2D barcodes encoding an NDC, serial number, lot number, and expiration date.




Photo courtesy of AmerisourceBergen. Mobile app displayed.

Both wholesalers scanned package barcodes in the same distribution centers, assessing the same types of products. AmerisourceBergen assessed specialty medications and McKesson focused on prescription pharmaceuticals.

The AmerisourceBergen team took a different scanning approach than in previous years by using a mobile application. “We created a mobile app that enables us to capture the data encoded in barcodes as well as note specific issues, analyze barcodes for specific criteria, and take photos of the issues that we find—all within the same entry. We can then share the analysis and pictures with manufacturers, giving them constructive feedback,” explains Ameer Ali, senior manager of Secure Supply Chain & Manufacturer Operations, AmerisourceBergen.

In 2019, the sample sizes for both AmerisourceBergen and McKesson included:

- AmerisourceBergen scanned 1,545 packages representing 270 manufacturers and 100% of on-hand specialty products. The new mobile application enabled AmerisourceBergen team members to work individually and capture all information in one place—a significant boost to productivity.
- McKesson scanned 16,314 packages representing 477 manufacturers. A team comprised of McKesson personnel scanned barcodes using production scanners, and captured scanned information in McKesson’s own production system.
- At both AmerisourceBergen and McKesson distribution centers, the GS1 Healthcare US team scanned more than 3,700 packages to provide an independent audit of the results. The analysis from the packages scanned by AmerisourceBergen, McKesson, and GS1 Healthcare US teams revealed a 99.9% accuracy of the audited items.

Ali with AmerisourceBergen says, “Conducting the audit in conjunction with the GS1 US assessment ensures that the information is reflective of the entire industry and measured against agreed upon standards.”

“We created a mobile app that enables us to capture the data encoded in barcodes as well as note specific issues, analyze barcodes for specific criteria, and take photos of the issues that we find—all within the same entry. We can then share the analysis and pictures with manufacturers, giving them constructive feedback.”

Ameer Ali
Senior Manager, Secure Supply Chain & Manufacturer Operations,
AmerisourceBergen

Specialty Products at AmerisourceBergen



1,545

packages scanned

representing 270 manufacturers

Homogeneous Cases at Cardinal Health

19,444

barcodes scanned

2D and linear barcodes on 7,996
cases from 177 manufacturers



Rx Products at McKesson



16,314

packages scanned

representing 477 manufacturers

Cardinal Health focused on homogeneous case-level barcodes on pharmaceutical products in its Groveport, Ohio National Logistics Center.

“This year, we wanted to see if there was an improvement year-over-year,” says Quentin Dittman, director of Operations Technology at Cardinal Health. “After last year’s assessment, we really dug into the data. We started talking with our suppliers, reaching out to understand any issues. This understanding was really crucial for us in order to push for the highest level of compliance. Bad barcodes mean bad problems for the supply chain.”

The *HDA Guidelines for Bar Coding in the Pharmaceutical Supply Chain* recommend that manufacturers use two linear barcodes with the NDC (GTIN) and serial number in one, and the lot number and expiration date in the other, or one 2D barcode encoding all four data elements.⁵ The Cardinal Health assessment encompassed both approaches.

A new addition to Cardinal Health’s scanning process was its own internal tool to conduct the analysis and validation of product data. “We call it the ‘barcode validator’ and it’s going to be used for our production going forward when we’re evaluating all of our suppliers’ barcodes,” says Dittman. “We thought it was really important for us to have an in-house tool and system.”

- Cardinal Health scanned 19,444 2D and linear barcodes on 7,996 cases from 177 manufacturers. This included both faster- and slower-moving ambient products from their racks, plus cold chain products stored in the refrigerator.
- At Cardinal Health, the GS1 Healthcare US team scanned 4,120 2D and linear barcodes on 1,548 cases.

“In my opinion, having GS1 US be part of the assessment by auditing the data was critical since they provide a third-party perspective on the quality of the data and process,” says Dittman. “They ensured that any data captured was verified, lending an extra layer of credibility to the results.”

“In my opinion, having GS1 US be part of the assessment by auditing the data was critical since they provide a third-party perspective on the quality of the data and process. They ensured that any data captured was verified, lending an extra layer of credibility to the results.”

Quentin Dittman
Director of Operations Technology, Cardinal Health

⁵ HDA (2017). HDA Guidelines for Bar Coding in the Pharmaceutical Supply Chain. Retrieved September 14, 2018 from <https://www.healthcaredistribution.org/resources/hda-guidelines-for-bar-coding-in-the-pharmaceutical-supply-chain>

Readable 2D GS1 DataMatrix Barcode With All Four DSCSA Data Elements



2019

Specialty Products

71.9%

scanned at AmerisourceBergen

Compared to 2018



Compared to 2017



2019

Homogeneous Cases

78.7% & **73.3%**

scanned at Cardinal Health with
2D (GS1 DataMatrix) barcodes

scanned at Cardinal Health
with linear (GS1-128) barcodes

Compared to 2018



2019

Rx Products

71%

scanned at McKesson

Compared to 2018



Compared to 2017



Exceeding Expectations

The results from the AmerisourceBergen and McKesson assessments showed a significantly higher year-over-year increase of nearly 52 percentage points when compared to the 2018 assessment, and 66 percentage points when compared to 2017.

In fact, all wholesalers were very pleased that suppliers exceeded their expectations of 50 percent to 60 percent.

- Of the specialty products at AmerisourceBergen, **71.9%** of all packages had a readable 2D GS1 DataMatrix barcode with all four DSCSA-required data elements (compared to 20.4% in 2018, and 7.2% in 2017).
- Similarly, the prescription products at McKesson, **71%** had a readable 2D GS1 DataMatrix barcode with all four DSCSA-required data elements (compared to 20.8% in 2018, and 6.5% in 2017).
- At Cardinal Health, **78.7%** of homogeneous cases with 2D (GS1 DataMatrix) barcodes and **73.3%** with linear barcodes had all four data elements (compared to 15.1% in 2018).

“The results just blew me away,” says Scott Mooney, vice president of Distribution Operations, Supply Chain Assurance, McKesson. “It was fantastic to see the percentage increase so high. Now, we just have to fill the gap to get to 100 percent.”

Dittman agrees, “The results are very exciting; they exceeded my expectations. And as we process more and more inventory, I expect to see the compliance reach up to 90 percent or even 100 percent.”

“The grandfathering allowance from the FDA was helpful to assure that supply chains remained stocked with inventory, and patients could get the proper medications that they needed, when they needed them. I think that there were far fewer manufacturers selling grandfathered product than might have been expected—given that we also saw such a high percentage of product with the 2D barcode.”

Scott Mooney

Vice President of Distribution Operations, Supply Chain Assurance,
McKesson Pharmaceutical

Top Observations

As part of the assessments, AmerisourceBergen, McKesson, and Cardinal Health noted the following observations:

High Levels of Serialized Inventory

U.S. FDA issued a [draft guidance](#), informing industry that it was delaying enforcement of the DSCSA requirements until November 2018, to provide manufacturers additional time and avoid supply disruptions.⁶

The AmerisourceBergen and McKesson assessments were conducted in May and July, respectively—at least six months after the November 2018 deadline.

“Of course, the compliance deadline really drove suppliers’ actions toward serialization,” says Ali. “We recently started seeing significantly more serialized products in our warehouse distribution network. So, the serialized inventory in the supply chain is steadily increasing as expected, with grandfathered inventory expected to continue to decrease over the next several months.”

Dittman adds, “Our manufacturing partners are burning through the backlog of inventory that they had produced when preparing to meet their 2018 serialization requirements. We’re getting to a point where all the products will soon be serialized as we’re seeing the expiration dates slide.”

Mooney from McKesson says, “The grandfathering allowance from the FDA was helpful to assure that supply chains remained stocked with inventory, and patients could get the proper medications that they needed, when they needed them. I think that there were far fewer manufacturers selling grandfathered product than might have been expected—given that we also saw such a high percentage of product with the 2D barcode.”

An additional year-over-year significant change was experienced with the average expiration date of products being 1.6 years in 2019, compared to 2.3 years in 2018. This could be a reflection of an industry build of inventory last year with lot-only based products, and in 2019, older inventory was consumed prior to the conversion of serialized packages.

Mooney points to the impressive effort by suppliers when making this change. While many of the suppliers may have a small number of products, many of them have 100-150 products that are manufactured in 10-12 different product facilities. “Our experience is that suppliers are not lagging behind,” explains Mooney. “A supplier that is not 100 percent may just have a facility that is delayed in getting the conversion completed to handle the 2D barcodes.”

Ali confirms that AmerisourceBergen saw that some manufacturers had a mixture of good and bad labels, most likely due to a variation of packaging locations and contract manufacturers.

Improved Expiration Date

AmerisourceBergen and McKesson also note the significant improvement of properly encoding the barcode with the expiration date—previously an issue in 2017 and 2018.

In previous assessment years, the wholesalers saw suppliers use “00” as the day in the expiration date. A secondary problem was that the day in the expiration date was not being included in the human readable, even when it was encoded in the barcode.

“Out of the 16,300 packages that we scanned, only 183 of these had expiration date issues,” advises McKesson’s Mooney. “This was a huge, positive change and will be especially important when we start exchanging data as trading partners.”

Mooney suspects that guidelines like the [GS1 US Implementation Guideline: Applying GS1 Standards for DSCSA and Traceability](#), helped suppliers make this shift.

Ali with AmerisourceBergen still warns about the impact on the supply chain when expiration dates are not encoded accurately, or human readable information is not labelled according to the guidelines. “Pharmacies, for example, that rely on human readable expiration dates may have difficulty accurately reading the information when dispensing pharmaceuticals to patients,” says Ali. “This could have a real impact on patient health, in addition to the supply chain.”

An additional year-over-year significant change was experienced with the average expiration date of products being 1.6 years in 2019, compared to 2.3 years in 2018. This could be a reflection of an industry build of inventory last year with lot-only based products, and in 2019, older inventory was consumed prior to the conversion of serialized packages.

6 United States. Department of Health and Human Services. FDA (June 2017). “FDA Issues Draft Guidance: Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy.” Accessed September 14, 2018 at: <https://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/ucm565358.htm>

Better Barcode Quality

Another area of improvement was the legibility of barcodes.

In 2017 and 2018, AmerisourceBergen and McKesson could not scan certain barcodes since they were applied on shiny surfaces or were printed in inappropriate colors.

“These kinds of problems were nearly absent this year,” says Mooney. “To the best of my knowledge, we had only two instances where we experienced barcodes in difficult-to-read colors or surfaces. With the quality barcodes, we were able to scan noticeably quicker.”

Dittman with Cardinal Health agrees that barcode quality improved, considering the amount of time required to make those changes. At the same time, Dittman advises it’s not quite where it needs to be. “I’d like to see everybody following the standard. Although there is a marked improvement, it’s not where it should be from a supply chain or downstream perspective.”

Cardinal Health, McKesson and AmerisourceBergen are all reaching out to their suppliers, providing one-on-one feedback on areas where improvements can be made.



“As we move more towards the data exchange of 2023, I think our ability to leverage the information available today becomes more acute. It’s making sure that we have the right pieces in place until we get to 2023 when we can then all unlock the complete value that’s promised today.”

Quentin Dittman

Director of Operations Technology, Cardinal Health

2019 Business Benefits

As suppliers “close the gap” for 100 percent readability, the next big step for wholesalers and suppliers alike will be using the data for more efficient processes.

“We begin using the data this November (2019) when we start doing saleable returns verification, confirming what’s encoded in the barcode against the data that manufacturers have kept on file,” says Mooney. “Many suppliers in the industry are working on getting the data organized and presentable for their verification returns program.”

“When all products have readable 2D barcodes, we can begin truly looking at the exchange of data and the incorporation of that data into our processes. We will be ‘marrying’ the physical product with its digital twin. In other words, every product will have a dual state—a digital version and physical version—that we will be able to match between our respective platforms. That’s what we are required to do in 2023.”

Scott Mooney

Vice President of Distribution Operations, Supply Chain Assurance, McKesson Pharmaceutical

Other process benefits for wholesalers include scanning barcodes to determine if a product’s expiration date is within acceptable limits, providing healthcare providers with the “go/no go” when dispensing of the product. “Today, we check for recalls manually by referring to the human readable on the package,” explains Mooney. “Now, with readable barcodes, we can harvest the data for increased efficiencies inside our distribution center.”

Dittman from Cardinal Health also references the potential for increased efficiencies in Cardinal’s distribution center as data is increasingly accessed from readable barcodes. “It starts at our front door when the product arrives in receiving. Barcodes help save us time, effort, and ultimately, labor costs. There’s also a quality impact since we’re limiting (or eliminating altogether) manual intervention where there’s a propensity for error.”

“As we move from more than 70 percent to 100 percent readable barcodes, we will continue to lay the foundation for exchanging data as part of the 2023 requirement.”

2023 Industry Value

Perhaps the most exciting results will be realized in 2023—just four short years away. “When all products have readable 2D barcodes, we can begin truly looking at the exchange of data and the incorporation of that data into our processes,” says Mooney. “We will be ‘marrying’ the physical product with its digital twin. In other words, every product will have a dual state—a digital version and physical version—that we will be able to match between our respective platforms. That’s what we are required to do in 2023.”

“I think the dilemma we will face is that there’s a strong appetite to quickly use this data,” continues Mooney. “But from a process perspective, we need to take the time required to move as an industry—one step at a time. We can start to test the exchange of serialized data, but ultimately, the entire industry will need to have data flowing back and forth between all trading partners. We’re looking at ‘how and when’ this becomes possible.”

Dittman says, “As we move more towards the data exchange of 2023, I think our ability to leverage the information available today becomes more acute. It’s making sure that we have the right pieces in place until we get to 2023 when we can then all unlock the complete value that’s promised today.”

Ali adds, “With full traceability planned for 2023, the ability to track and communicate across the supply chain will be down to the unique lowest saleable unit. This has never been available before and will unlock value and increase accuracy and specificity to new levels. Until then, the objective is to work to eliminate physical and data exceptions, and add the processes and equipment necessary to enable the capture, verification, and exchange of this information between stakeholders.”

“With full traceability planned for 2023, the ability to track and communicate across the supply chain will be down to the unique lowest saleable unit. This has never been available before and will unlock value and increase accuracy and specificity to new levels. Until then, the objective is to work to eliminate physical and data exceptions, and add the processes and equipment necessary to enable the capture, verification, and exchange of this information between stakeholders.”

Ameer Ali
Senior Manager, Secure Supply Chain & Manufacturer Operations,
AmerisourceBergen

Learn More

Visit www.gs1us.org/dscsa.

About the Companies



About AmerisourceBergen

AmerisourceBergen Corporation is one of the world's largest pharmaceutical services companies, serving global markets with a focus on the pharmaceutical supply chain. Servicing pharmacies, providers and pharmaceutical manufacturers, the company provides global product sourcing and distribution and related solutions designed to improve product access, increase supply chain efficiency and enhance patient care. www.amerisourcebergen.com



About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks among the top 25 on the Fortune 500. www.cardinalhealth.com



About McKesson Pharmaceutical

McKesson Corp. is a global health services and information technology company, which provides medicines, pharmaceutical and care management products. It operates through the McKesson Distribution Solutions and McKesson Technology Solutions segments. The McKesson Distribution Solutions, which includes McKesson US Pharmaceutical, distributes ethical and proprietary drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America. This segment also provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, provides financial, operational and clinical solutions for pharmacies. www.mckesson.com



About GS1 Healthcare US

GS1 Healthcare US® is an industry group that focuses on driving the adoption and implementation of GS1 Standards in the healthcare industry in the United States to help improve patient safety and supply chain efficiency. GS1 Healthcare US brings together members from all segments of the healthcare industry to address the supply chain issues that most impact healthcare in the United States. Facilitated by GS1 US, GS1 Healthcare US is one of over 30 local GS1 Healthcare user groups around the world that supports the adoption and implementation of global standards developed by GS1. www.gs1us.org/healthcare

Proprietary Statement

This document contains proprietary information of GS1 US. Such proprietary information may not be changed for use with any other parties for any other purpose without the expressed written permission of GS1 US.

Improvements

Improvements and changes are periodically made to publications by GS1 US. All material is subject to change without notice. Please refer to GS1 US website for the most current publication available.

Disclaimer

Except as may be otherwise indicated in specific documents within this publication, you are authorized to view documents within this publication, subject to the following:

1. You agree to retain all copyright and other proprietary notices on every copy you make.
2. Some documents may contain other proprietary notices and copyright information relating to that document. You agree that GS1 US has not conferred by implication, estoppels, or otherwise any license or right under any patent, trademark, or copyright (except as expressly provided above) of GS1 US or of any third party.

This publication is provided “as is” without warranty of any kind, either express or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Any GS1 US publication may include technical inaccuracies or typographical errors. GS1 US assumes no responsibility for and disclaims all liability for any errors or omissions in this publication or in other documents which are referred to within or linked to this publication. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

Several products and company names mentioned herein may be trademarks and/or registered trademarks of their respective companies. GS1 US does not, by promulgating this document on behalf of the parties involved in the creation of this document, represent that any methods, products, and/or systems discussed or recommended in the document do not violate the intellectual property rights of any third party. GS1 US has not performed a search to determine what intellectual property may be infringed by an implementation of any strategies or suggestions included in this document. GS1 US hereby disclaims any liability for any party's infringement of intellectual property rights that arise as a result of any implementation of strategies or suggestions included in this document.

This publication may be distributed internationally and may contain references to GS1 US products, programs, and services that have not been announced in your country. These references do not imply that GS1 US intends to announce such products, programs, or services in your country.

GS1 US shall not be liable for any consequential, special, indirect, incidental, liquidated, exemplary, or punitive damages of any kind or nature whatsoever, or any lost income or profits, under any theory of liability, arising out of the use of this publication or any content herein, even if advised of the possibility of such loss or damage or if such loss or damage could have been reasonably foreseen.

GS1 US HEREBY DISCLAIMS, AND YOU HEREBY EXPRESSLY RELEASE GS1 US FROM, ANY AND ALL LIABILITY RELATING TO YOUR COMPLIANCE WITH REGULATORY STANDARDS AND LAWS, INCLUDING ALL RULES AND REGULATIONS PROMULGATED THEREUNDER. GS1 US MAKES NO WARRANTIES OF ANY KIND RELATING TO THE SUITABILITY OF THE GS1 STANDARDS AND THE SPECIFIC DOCUMENTS WITHIN THIS PUBLICATION TO COMPLY WITH ANY REGULATORY STANDARDS, LAWS, RULES AND REGULATIONS. ALL INFORMATION AND SERVICES ARE PROVIDED “AS IS.”

*GS1 US employees are not representatives or agents of the U.S. FDA, and the content of this publication has not been reviewed, approved, or authorized by the U.S. FDA. The following information contained herein is for informational purposes only as a convenience, and is not legal advice or a substitute for legal counsel. GS1 US Inc. assumes no liability for the use or interpretation of the information contained herein.

No Liability for Consequential Damage

In no event shall GS1 US or anyone else involved in the creation, production, or delivery of the accompanying documentation be liable for any damages whatsoever (including, without limitation, damages for loss of business profits, business interruption, loss of business information, or other loss) arising out of the use of or the results of use of or inability to use such documentation, even if GS1 US has been advised of the possibility of such damages.

IAPMO


In this publication, the letters “U.P.C.” are used solely as an abbreviation for the “Universal Product Code” which is a product identification system. They do not refer to the UPC, which is a federally registered certification mark of the International Association of Plumbing and Mechanical Officials (IAPMO) to certify compliance with a Uniform Plumbing Code as authorized by IAPMO.

*If applicable

GS1 US Corporate Headquarters

Princeton South Corporate Center, 300 Charles Ewing Boulevard
Ewing, NJ 08628 USA
T +609.620.0200 | E info@gs1us.org
www.gs1us.org

Connect With Us



6 14141 02698 2